NYSE:AORTMedical Equipment
Does Slower AMDS Uptake Recast Artivion’s Core Growth Narrative (AORT)
Earlier in 2026, Artivion reported first-quarter results that were broadly in line with expectations but reduced its full-year outlook after slower-than-anticipated starter set sales for its AMDS aortic device, despite reporting a 12% non-GAAP constant currency revenue increase.
This combination of solid headline growth with softer uptake of a key new product highlights how execution on AMDS adoption is central to Artivion’s growth story.
We’ll now examine how the lowered full-year outlook...